Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: $18.2 million for Q3 2024, compared to $13.1 million in Q3 2023. Net Loss: $54.4 million for Q3 2024, compared to $38.6 million in Q3 2023. Noncash Share-Based Compensation Expense: $8.3 million for Q3 2024, compared to $7.1 million in Q3 2023. Cash, Cash Equivalents, and Short-Term Investments: $455.3 million as of September 30, 2024, up from $424 million as of December 31, 2023. Warning! GuruFocus has detected 1 Warning Sign with KURA. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Kura Oncology Inc ( NASDAQ:KURA ) reported promising preliminary data from their KOMET-007 trial, showing ziftomenib's potential best-in-class safety and tolerability profile. The company has advanced all four cohorts in the Phase Ia dose escalation portion of KOMET-007 to the Phase Ib expansion study, indicating positive progress in their clinical trials. Ziftomenib
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Bank of America Co. from $36.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.MarketBeat
- Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]Yahoo! Finance
- Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
KURA
Earnings
- 11/7/24 - Beat
KURA
Sec Filings
- 11/20/24 - Form 8-K
- 11/19/24 - Form 4
- 11/18/24 - Form 144
- KURA's page on the SEC website